Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitors

被引:132
作者
Serrao, Erik [1 ]
Odde, Srinivas [1 ]
Ramkumar, Kavya [1 ]
Neamati, Nouri [1 ]
机构
[1] Univ So Calif, Sch Pharm, Dept Pharmacol & Pharmaceut Sci, Los Angeles, CA 90089 USA
来源
RETROVIROLOGY | 2009年 / 6卷
关键词
IMMUNODEFICIENCY-VIRUS-INFECTION; ACTIVE ANTIRETROVIRAL THERAPY; STRAND TRANSFER; CLINICAL-TRIAL; POTENT; RESISTANCE; DESIGN; PYRIMIDONES; POPULATIONS; ZIDOVUDINE;
D O I
10.1186/1742-4690-6-25
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Merck's MK-0518, known as raltegravir, has recently become the first FDA-approved HIV-1 integrase (IN) inhibitor and has since risen to blockbuster drug status. Much research has in turn been conducted over the last few years aimed at recreating but optimizing the compound's interactions with the protein. Resulting me-too drugs have shown favorable pharmacokinetic properties and appear drug-like but, as expected, most have a highly similar interaction with IN to that of raltegravir. We propose that, based upon conclusions drawn from our docking studies illustrated herein, most of these me-too MK-0518 analogues may experience a low success rate against raltegravir-resistant HIV strains. As HIV has a very high mutational competence, the development of drugs with new mechanisms of inhibitory action and/or new active substituents may be a more successful route to take in the development of second- and third-generation IN inhibitors.
引用
收藏
页数:14
相关论文
共 74 条
[1]  
Al-Mawsawi LQ, 2008, EXPERT OPIN EMERG DR, V13, P213, DOI [10.1517/14728214.13.2.213, 10.1517/14728214.13.2.213 ]
[2]  
[Anonymous], RANDOMIZED PLACEBO C
[3]  
[Anonymous], [No title captured], Patent No. 9950245
[4]  
[Anonymous], AIDS EP UPD
[5]   HIV-1 integrase: Structural organization, conformational changes, and catalysis [J].
Asante-Appiah, E ;
Skalka, AM .
ADVANCES IN VIRUS RESEARCH, VOL 52, 1999, 52 :351-369
[6]   How many "me-too" drugs are enough? The case of physician preferences for specific statins [J].
Austin, PC ;
Mamdani, MM ;
Juurlink, DN .
ANNALS OF PHARMACOTHERAPY, 2006, 40 (06) :1047-1051
[7]  
Billich Andreas, 2003, Curr Opin Investig Drugs, V4, P206
[8]  
Brown P. O., 1997, P161
[9]  
*CDCP, 2006, US BED HIV 1 CAPT EI
[10]   Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy [J].
Chun, TW ;
Stuyver, L ;
Mizell, SB ;
Ehler, LA ;
Mican, JAM ;
Baseler, M ;
Lloyd, AL ;
Nowak, MA ;
Fauci, AS .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (24) :13193-13197